Federal Register / Vol. 87, No. 115 / Wednesday, June 15, 2022 / Notices 36131 

3COVID–19 Vaccines Work, Centers for Disease 

Control and Prevention, https://www.cdc.gov/ 

coronavirus/2019-ncov/vaccines/effectiveness/ 

work.html (updated Dec. 23, 2021). See also 

Thompson MG, Natarajan K, Irving SA, et al. 

Effectiveness of a Third Dose of mRNA Vaccines 

Against COVID–19–Associated Emergency 

Department and Urgent Care Encounters and 

Hospitalizations Among Adults During Periods of 

Delta and Omicron Variant Predominance—VISION 

Network, 10 States, August 2021–January 2022. 

MMWR Morb Mortal Wkly Rep 2022;71:139–145 

(Jan. 28, 2022). DOI: http://dx.doi.org/10.15585/ 

mmwr.mm7104e3 (attributing decline of vaccine 

effectiveness to waning vaccine-induced immunity 

over time, possible increased immune evasion by 

SARS–CoV–2 variants, or a combination of these 

and other factors and finding that receiving a 

booster shot was highly effective at preventing 

COVID–19-associated emergency department and 

urgent care encounters and preventing COVID–19- 

associated hospitalizations). 

4COVID Data Tracker, Centers for Disease 

Control and Prevention, https://covid.cdc.gov/ 

covid-data-tracker/#vaccinations_vacc-peopleonedose-pop-5yr (last visited June 10, 2022). 

5COVID Data Tracker Weekly Review: The Time 

Is Now—Interpretive Summary for June 3, 2022, 

Centers for Disease Control and Prevention, https:// 

www.cdc.gov/coronavirus/2019-ncov/covid-data/ 

covidview/index.html (June 3, 2022). 

6COVID–19 Vaccine Boosters, Centers for Disease 

Control and Prevention, https://www.cdc.gov/ 

coronavirus/2019-ncov/vaccines/boostershot.html#second-booster (updated May 24, 2022). 

7National COVID–19 Preparedness Plan—March 

2022, https://www.whitehouse.gov/wp-content/ 

uploads/2022/03/NAT-COVID-19-PREPAREDNESSPLAN.pdf (last visited Mar. 30, 2022). Antiviral 

pills will also be added to the stockpile for the first 

time. See also Information About COVID–19 EUAs 

for Medical Devices, U.S. Food and Drug 

Administration, https://www.fda.gov/emergencypreparedness-and-response/mcm-legal-regulatoryand-policy-framework/emergency-useauthorization#coviddrugs (updated June 3, 2022); 

FDA News Release: Coronavirus (COVID–19) 

Update: FDA Authorizes First Oral Antiviral for 

Treatment of COVID–19, U.S. Food and Drug 

Administration, https://www.fda.gov/news-events/ 

press-announcements/coronavirus-covid-19- 

update-fda-authorizes-first-oral-antiviral-treatmentcovid-19 (Dec. 22, 2021). 

8Science Brief: Indicators for Monitoring COVID– 

19 Community Levels and Making Public Health 

Recommendations, Centers for Disease Control and 

Prevention, https://www.cdc.gov/coronavirus/2019- 

ncov/science/science-briefs/indicators-monitoringcommunity-levels.html (updated Mar. 4, 2022); 

Nationwide COVID–19 Infection- and VaccinationInduced Antibody Seroprevalence (Blood 

donations), Centers for Disease Control and 

Prevention, https://covid.cdc.gov/covid-datatracker/#nationwide-blood-donor-seroprevalence 

(last updated Feb. 18, 2022). 

9This Order is not a legislative rule within the 

meaning of the Administrative Procedure Act 

(‘‘APA’’) but rather a rescission of a previous Order 

undertaken as an emergency action under the 

existing authority of 42 U.S.C. 264(a) and 42 CFR 

71.20, 71.31(b), which was taken without notice 

and comment. In the event that a court determines 

this rescission qualifies as a legislative rule under 

the APA, notice and comment and a delay in 

effective date are not required because the prior 

Order was established without notice and comment 

and there is good cause to lift that restriction 

immediately, given the current judgment that it is 

unnecessary to prevent the introduction of COVID– 

19 into the United States and to seek comment prior 

to the effective date of this notice would be 

impracticable and contrary to the public interest. 5 

U.S.C. 553(b)(3)(B). Further, while this Order is 

major under the Congressional Review Act ‘‘CRA’’, 

it is not necessary to delay the effective date for 

similar reasons of good cause. 5 U.S.C. 808(2). 

Vaccines, including boosters, 

continue to be the most important 

public health tool for fighting COVID– 

19, and CDC recommends that all 

people get vaccinated against COVID–19 

as soon as they are eligible and stay up 

to date with their vaccinations.3 When 

the Order was first issued in January 

2021, the United States and countries 

around the world were just embarking 

on efforts to vaccinate their populations 

and learn about emerging variants. Now, 

as of June 9, 2022, 70.9% of the U.S. 

population five years of age and older 

has received a primary series.4

Additionally, booster shots are 

recommended for and available to 

individuals five years of age and older; 5

second booster shots are now 

recommended for adults ages 50 years 

or older and people ages 12 years and 

older who are moderately or severely 

immunocompromised.6 The increased 

percentage of individuals who are not 

only fully vaccinated with a primary 

series but have also received one or 

more booster doses strengthens 

community and individual protection 

against serious illness from SARS–CoV– 

2 and reduces the associated strain on 

healthcare infrastructure. We know that 

the now-dominant Omicron variant, 

though more transmissible than prior 

variants, has generally caused less 

severe disease among those who are 

infected. COVID–19 vaccination still 

remains an effective measure to prevent 

medically significant disease, 

hospitalizations, and deaths. 

Similarly, the availability of 

efficacious and accessible treatments 

adds a powerful layer of protection 

against severe COVID–19 that was not 

available in January 2021.7 The U.S. 

Government’s commitment to making 

such medications available and the 

ability to produce variant-specific 

treatments are critical components of 

the next phase of the fight against 

COVID–19. The observed reduction in 

severity of COVID–19 cases and ongoing 

effective use of pharmaceutical 

interventions contribute greatly to 

minimize medically significant disease 

and largely prevent excessive strain on 

the healthcare sector at this stage in the 

pandemic.8

Therefore, based on these 

considerations, I have concluded that 

continuation of the Order is not 

currently necessary.9 There being no 

operational need to delay 

implementation of this rescission for 

more than a short period of time, it shall 

take effect for all aircraft departing from 

their point of origin on or after Sunday, 

June 12, 2022, at 12:01 a.m. Eastern 

Daylight Time (EDT). Importantly, CDC 

continues to recommend that all 

travelers remain up to date with 

vaccination against COVID–19 and get 

tested for current infection with a viral 

test before and after they travel, and 

after any known exposure to a person 

with COVID–19, so they can take 

appropriate precautions to reduce the 

risk of transmission while infectious. 

Furthermore, CDC continues to 

recommend that people wear masks in 

indoor public transportation settings. 

Effective Date 

This rescission shall be effective for 

all aircraft departing their point of 

origin on or after June 12, 2022, at 12:01 

a.m. EDT. 

Sherri Berger, 

Chief of Staff, Centers for Disease Control 

and Prevention. 

[FR Doc. 2022–13022 Filed 6–13–22; 4:15 pm] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Award of a Single-Source 

Cooperative Agreement To Fund 

Ministry of Health (MOH)—Trinidad & 

Tobago (TT) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), announces the 

award of approximately $2,000,000 for 

Year 1 of funding to the Ministry of 

Health– Trinidad & Tobago. This award 

will help build national capacity of TT 

to treat HIV and other diseases of public 

health importance impacting people 

living with HIV (PLHIV) and 

populations affected by HIV, as well as 

move progress towards achieving the 

95–95–95 goals and ensure sustainable 

control of the epidemic in TT. Funding 

amounts for years 2–5 will be set at 

continuation. 

DATES: The period for this award will be 

September 30, 2022, through September 

29, 2027. 

FOR FURTHER INFORMATION CONTACT: 

Douan Kirivong, Center for Global 

Health, Centers for Disease Control and 

Prevention, 142 Old Hope Road, 


jspears on DSK121TN23PROD with NOTICES1
36132 Federal Register / Vol. 87, No. 115 / Wednesday, June 15, 2022 / Notices 

Kingston 6, Jamaica, Telephone: 800– 

232–6348, Email: bpq7@cdc.gov. 

SUPPLEMENTARY INFORMATION: The 

single-source award will provide high 

quality prevention, care, and treatment 

services for PLHIV; strengthen strategic 

health information; and provide 

equitable access to comprehensive 

public health services addressing PLHIV 

and other diseases impacting PLHIV in 

TT. 

The Ministry of Health is in a unique 

position to conduct this work, as it is 

the national authority charged with 

oversight of the entire health system in 

TT. The HIV and AIDS Coordinating 

Unit (HACU) in the MOH leads the 

Ministry of Health’s response in 

reducing the incidence of HIV infections 

in TT and mitigating the impact of HIV/ 

AIDS in persons infected and affected 

nationwide. 

Summary of the Award 

Recipient: Ministry of Health 

(MOH)—Trinidad & Tobago (TT). 

Purpose of the Award: The purpose of 

the award is to help build national 

capacity of TT to treat HIV and other 

diseases of public health importance 

impacting PLHIV and populations 

affected by HIV, as well as move 

progress towards achieving the 95–95– 

95 goals and ensure sustainable control 

of the epidemic in TT. 

Amount of Award: The approximate 

year 1 funding amount will be 

$2,000,000 in Federal Fiscal Year (FYY) 

2022 funds, subject to the availability of 

funds. Funding amounts for years 2–5 

will be set at continuation. 

Authority: This program is authorized 

under Public Law 108–25 (the United 

States Leadership Against HIV AIDS, 

Tuberculosis and Malaria Act of 2003). 

Period of Performance: September 30, 

2022, through September 29, 2027. 

Dated: June 9, 2022. 

Terrance Perry, 

Chief Grants Management Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. 2022–12847 Filed 6–14–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Public Health Service Act (PHS), 

Delegation of Authority 

Notice is hereby given that I have 

delegated to the Director, National 

Institute for Occupational Safety and 

Health, Centers for Disease Control and 

Prevention (CDC), without authority to 

redelegate, all authorities vested in the 

Secretary, under Sections 2695G–2695I, 

Title XXVI of the PHS Act (42 U.S.C. 

300ff–138—300ff–140), as amended. 

This may not be redelegated. 

This delegation is effective upon date 

of signature. In addition, I hereby affirm 

and ratify any actions taken by you or 

your subordinates which involved the 

exercise of the authorities delegated 

herein prior to the effective date of this 

delegation. 

Dated: June 9, 2022. 

Xavier Becerra, 

Secretary. 

[FR Doc. 2022–12829 Filed 6–14–22; 8:45 am] 

BILLING CODE 4160–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Notice of Award of a Single-Source 

Cooperative Agreement To Fund 

Zambia National Public Health Institute 

(ZNPHI) 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice. 

SUMMARY: The Centers for Disease 

Control and Prevention (CDC), located 

within the Department of Health and 

Human Services (HHS), announces the 

award of approximately $10,000,000 

with an expected total funding of 

approximately $50,000,000 over a 5-year 

period, to Zambia National Public 

Health Institute. The award will 

strengthen ZNPHIs’ public health 

capacity and to support ZNPHI to work 

with countries to build strong National 

Public Health Institutes in the region. 

The CDC seeks to strengthen NPHIs that 

are credible, technically expert, and 

prioritize the protection of the public’s 

health. 

DATES: The period for this award will be 

September 30, 2022, through September 

29, 2027. 

FOR FURTHER INFORMATION CONTACT: 

Shana Eatman, Centers for Disease 

Control and Prevention, 1825 Century 

Center, MS V18–3, Atlanta, GA 30345, 

Telephone: 770–488–3933, E-Mail: 

DGHPNOFOs@cdc.gov. 

SUPPLEMENTARY INFORMATION: The 

single-source award will allow ZNPHI 

to implement effective surveillance, 

laboratory, response, and capacity 

building functions to enhance the wellbeing of people in Zambia. ZNPHI will 

efficiently manage its responsibilities 

through transparent and data-driven 

decision making, robust organizational 

capacities, and effective internal/ 

external stakeholder communication. 

ZNPHI will also work with other 

government of Zambia entities to 

implement public health strengthening 

activities. Likewise, ZNPHI will work 

with other National Public Health 

Institutes or Ministries of Health in the 

region to develop or strengthen their 

public health capacities and functions. 

Zambia National Public Health 

Institute is in a unique position to 

conduct this work. ZNPHI was 

established in 2015 and operated under 

MOH authorities for several years. 

During this time, they have been funded 

by the Zambian government and other 

partners. The ZNPHI Act was passed in 

2020, which officially established 

ZNPHI as an independent agency and 

the main institution responsible for 

public health and the national focal 

point for implementation of the 

International Health Regulations. 

ZNPHI’s mandate also includes 

responsibility for the health security for 

the nation through the establishment 

and functioning of the public health 

emergency operations center; national 

public health laboratory; surveillance; 

workforce development and through the 

coordination of public and global health 

security. 

Summary of the Award 

Recipient: Zambia National Public 

Health Institute (ZNPHI). 

Purpose of the Award: The purpose of 

this award is to strengthen ZNPHIs’ 

public health capacity and to support 

ZNPHI to work with countries to build 

strong National Public Health Institutes 

in the region. The CDC seeks to 

strengthen NPHIs that are credible, 

technically expert, and prioritize the 

protection of the public’s health. 

Amount of Award: $10,000,000 in 

Federal Fiscal Year (FFY) 2022 funds, 

with a total estimated $50,000,000 for 

the 5-year period of performance, 

subject to availability of funds. Please 

note, this NOFO funding strategy is as 

follows: $2,000,000 for Core Component 

1, and $8,000,000 in Approved but 

Unfunded (ABU) Components. 

Authority: This program is authorized 

under Section 307 of the Public Health 

Service Act [42 U.S.C. 242I] and Section 

301(a) [42 U.S.C. 241(a)] of the Public 

Health Service Act. 

Period of Performance: September 30, 

2022, through September 29, 2027. 


jspears on DSK121TN23PROD with NOTICES1